       Document 0126
 DOCN  M9610126
 TI    [New vaccines. What can we expect in the coming years?]
 DT    9601
 AU    Bjune G; Nokleby HM; Avdeling for vaksine, Statens institutt for
       folkehelse, Oslo.
 SO    Tidsskr Nor Laegeforen. 1995 Oct 10;115(24):3032-4. Unique Identifier :
       AIDSLINE MED/96038696
 AB    There is an urgent need for new vaccines. The biotechnological
       revolution has created new hope. However, developments are hampered by
       inadequate basic knowledge about the immunology of infections, and lack
       of coordination between public and commercial research and development
       work on vaccines. Recombinant vaccines are an important step forward
       when combined with new adjuvants, but the authorization of these
       adjuvants for use in humans has been slow. Recombinant live vectors for
       vaccine antigens circumvent this problem, but imply some risk in
       HIV-infected people. Nucleic acid vaccines are met with strong emotional
       resistance, because of many unanswered questions as to their safety.
       Mucosal vaccines make quality control simpler, open up for a safer use
       of live recombinant vectors and simplify delivery of the vaccine. New
       vaccines marketed in the last decade are surprisingly old-fashioned.
       Traditional ways of making vaccines have still not been abandoned.
 DE    Bacterial Vaccines/GENETICS/*SUPPLY & DISTRIBUTION  English Abstract
       Forecasting  Human  Viral Vaccines/GENETICS/*SUPPLY & DISTRIBUTION
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

